4.4 Article

Structural gray matter abnormalities in migraine relate to headache lateralization, but not aura

期刊

CEPHALALGIA
卷 35, 期 1, 页码 3-9

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102414532378

关键词

Migraine; aura; brain structure; magnetic resonance imaging

资金

  1. University of Copenhagen
  2. Lundbeck Foundation Center for Neurovascular Signalling (LUCENS)
  3. Danish Council for Independent Research-Medical Sciences (FSS) [271-08-0446]
  4. Novo Nordisk Foundation [R172-A14333]
  5. Research Foundation of the Capital Region of Denmark
  6. Novo Nordisk Fonden [NNF11OC1014333] Funding Source: researchfish

向作者/读者索取更多资源

Background: The hallmark of migraine aura (MA) is transient cortical dysfunction but it is not known if MA is associated with structural cortical or subcortical changes. To determine the relation between MA and structural gray matter abnormalities, we studied a unique sample of 20 patients with frequent side-locked MA, i.e. visual aura consistently occurring in the same hemifield. Methods: We applied a highly sensitive within-patient design to assess anatomical differences with both voxel-based morphometry and surface-based morphometry on a whole-hemisphere level and for specific anatomical regions of interest. Within-subject comparisons were made with regard to aura symptoms (N = 20 vs 20) and with regard to headache (N = 13 vs 13). Results: We found no differences in gray matter structure with regard to aura symptoms in MA patients. Comparing the typical migraine headache side of the patients to the contralateral side revealed a difference in cortical thickness in the inferior frontal gyrus (mean difference 0.12 mm, p = 0.036). Conclusion: MA per se is associated with abnormal function but not with lateralized abnormalities of gray matter structure. Alteration of the inferior frontal cortex suggests structural reorganization of pain inhibitory circuits in response to the repeated intense nociceptive input due to the headache attacks.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Anesthesiology

Adenosine causes short-lasting vasodilation and headache but not migraine attacks in migraine patients: a randomized clinical trial

Janu Thuraiaiyah, Mohammad Al-Mahdi Al-Karagholi, Fatima Azzahra Elbahi, Zixuan Alice Zhuang, Messoud Ashina

Summary: In a randomized, double-blinded, placebo-controlled, crossover study, researchers found that adenosine does not significantly induce migraine attacks but does cause headache. Adenosine increases heart rate, facial skin blood flow, and superficial temporal artery diameter, while decreasing middle cerebral artery blood flow.
Article Clinical Neurology

Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis

C. Tsagkas, A. Horvath-Huck, T. Haas, M. Amann, A. Todea, A. Altermatt, J. Mueller, A. Cagol, M. Leimbacher, M. Barakovic, M. Weigel, S. Pezold, T. Sprenger, L. Kappos, O. Bieri, C. Granziera, P. Cattin, K. Parmar

Summary: This study proposes a novel automatic segmentation method for spinal cord compartments in patients with multiple sclerosis (MS) and compares it with manual segmentation. The results demonstrate that the automatic method shows higher reproducibility and accuracy compared to manual segmentation, and reveal that patients with MS have reduced areas in specific spinal cord tissue compartments.

AMERICAN JOURNAL OF NEURORADIOLOGY (2023)

Review Clinical Neurology

Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies

Irene de Boer, Iris Elsa Verhagen, Marcio Nattan Portes Souza, Messoud Ashina

Summary: New acute therapies such as ditans and gepants may be effective alternatives for patients who cannot use or do not respond to triptans. However, further studies are needed to determine their place and safety in migraine treatment.

CEPHALALGIA (2023)

Review Clinical Neurology

Prolactin in headache and migraine: A systematic review of clinical studies

Mohammad Al-Mahdi Al-Karagholi, Veberka Kalatharan, Hashmat Ghanizada, Christian Gram, Gregory Dussor, Messoud Ashina

Summary: This systematic review examined clinical studies on the role of prolactin and its receptors in headache and migraine. The findings suggest that prolactin and its receptors play a key role in migraine pathophysiology. Further randomized and placebo-controlled clinical studies are needed to clarify the influence of prolactin in migraine attack initiation.

CEPHALALGIA (2023)

Article Clinical Neurology

Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial

Messoud Ashina, Stewart J. Tepper, Uwe Reuter, Andrew M. Blumenfeld, Susan Hutchinson, Jing Xia, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman

Summary: This study assessed the long-term safety, tolerability, and efficacy of once-daily oral atogepant 60 mg in adults with migraine. The results showed that daily use of atogepant for preventive treatment of migraine during this 1-year trial was safe, well tolerated, and efficacious.

HEADACHE (2023)

Review Clinical Neurology

Migraine aura-like episodes following sclerotherapy for varicose veins of the lower extremities-A systematic review

Lionesa Bahtiri, Andreas Vinther Thomsen, Messoud Ashina, Anders Hougaard

Summary: This systematic review summarizes and evaluates cases of migraine aura-like episodes triggered by sclerotherapy of veins of the lower extremities, and explores possible underlying mechanisms.

HEADACHE (2023)

Article Clinical Neurology

Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis

Alessandro Cagol, Nuria Cerda Fuertes, Marc Stoessel, Muhamed Barakovic, Sabine Schaedelin, Marcus D'Souza, Jens Wurfel, Alexander U. Brandt, Ludwig Kappos, Till Sprenger, Yvonne Naegelin, Jens Kuhle, Cristina Granziera, Athina Papadopoulou

Summary: This study investigated the associations among OCT changes, MRI measurements of brain volume loss, and physical and cognitive impairment in patients with multiple sclerosis. The results showed that OCT measures of pRNFL and GCIPL were associated with volumes of gray matter structures, and inversely correlated with T2-lesion volume. These findings highlight the value of OCT as markers of neurodegeneration and disability in multiple sclerosis.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis

Charidimos Tsagkas, Antal Huck-Horvath, Alessandro Cagol, Tanja Haas, Muhamed Barakovic, Michael Amann, Esther Ruberte, Lester Melie-Garcia, Matthias Weigel, Simon Pezold, Regina Schlaeger, Jens Kuhle, Till Sprenger, Ludwig Kappos, Oliver Bieri, Philippe Cattin, Cristina Granziera, Katrin Parmar

Summary: Spinal cord atrophy of the cervical anterior horn is clinically relevant in multiple sclerosis (MS) patients, particularly in progressive MS (PMS) patients and at the level of cervical SC enlargement.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis

Charidimos Tsagkas, Antal Huck-Horvath, Alessandro Cagol, Tanja Haas, Michael Amann, Muhamed Barakovic, Esther Ruberte, Lester Melie-Garcia, Matthias Weigel, Simon Pezold, Regina Schlaeger, Jens Kuhle, Till Sprenger, Ludwig Kappos, Oliver Bieri, Philippe Cattin, Cristina Granziera, Katrin Parmar

Summary: This study investigated longitudinal changes of cervical spinal cord (cSC) gray and white matter areas in multiple sclerosis (MS) patients. The results showed that patients with clinical progression had a faster reduction of cSC areas over time compared to stable patients. Additionally, compared to patients without clinical progression and healthy controls, only patients with clinical progression demonstrated a preferential reduction of cSC and white matter areas at the level of cSC enlargement.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial

Messoud Ashina, Caroline Roos, Lily Qian Li, Mika Komori, David Ayer, Dustin Ruff, John Henry Krege

Summary: During the 12-month extension study, patients treated with lasmiditan showed significant improvements in migraine-related disability and quality of life. No new safety concerns were identified.

CEPHALALGIA (2023)

Article Clinical Neurology

Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis

Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Andrea Wang, Sunfa Cheng, Jan Klatt, Daniel D. Mikol

Summary: This study evaluated the long-term efficacy and safety of erenumab in patients with chronic migraine. The results showed that long-term treatment with erenumab could consistently reduce monthly migraine days and the efficacy was similar in patients with and without acute medication overuse.

HEADACHE (2023)

Review Clinical Neurology

Prolactin in headache and migraine: A systematic review of preclinical studies

Mohammad Al-Mahdi Al-Karagholi, Veberka Kalatharan, Hashmat Ghanizada, Gregory Dussor, Messoud Ashina

Summary: The review aimed to investigate the role of prolactin signaling in the pathophysiology of headache and migraine. Sex-dependent features of migraines suggest the involvement of the hypothalamus-pituitary-gonadal axis. Prolactin signaling has been implicated in sex-related differences in pain perception.

HEADACHE (2023)

Article Clinical Neurology

Glibenclamide Posttreatment Does Not Inhibit Levcromakalim Induced Headache in Healthy Participants: A Randomized Clinical Trial

Lili Kokoti, Mohammad Al-Mahdi Al-Karagholi, Cherie Amalie Waldorff Nielsen, Messoud Ashina

Summary: This study investigated the effect of the K-ATP channel blocker glibenclamide on levcromakalim-induced headache in healthy volunteers and found that glibenclamide did not attenuate levcromakalim-induced headache. Future studies should further explore the role of different isoforms of sulfonylurea receptor subunits of K-ATP channels in the pathogenesis of headache and migraine.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial

Messoud Ashina, Richard B. Lipton, Jessica Ailani, Jan Versijpt, Simona Sacco, Dimos D. Mitsikostas, Cecilie Laurberg Christoffersen, Bjorn Sperling, Anders Ettrup

Summary: This post hoc analysis suggests that eptinezumab can reduce monthly migraine days in patients with difficult-to-treat migraines. The majority of patients who responded to eptinezumab during the initial weeks maintained or improved their response during the later weeks. Additionally, a significant number of initial non-responders showed a response after the second infusion.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis

Messoud Ashina, Dimos D. Mitsikostas, Verena Ramirez Campos, Steve Barash, Xiaoping Ning, Hans-Christoph Diener

Summary: This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial. The results showed that the NNT, NNH, and LHH for quarterly and monthly fremanezumab compare favorably with those for traditional oral preventive medications, including topiramate, valproate, and propranolol.

HEADACHE (2023)

暂无数据